Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancers
Conditions
Advanced Cancers
Trial Timeline
Feb 1, 2009 → Feb 4, 2018
NCT ID
NCT00836927About Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion
Ridaforolimus Tablet + Ridaforolimus Intravenous (IV) Infusion is a phase 2 stage product being developed by Merck for Advanced Cancers. The current trial status is terminated. This product is registered under clinical trial identifier NCT00836927. Target conditions include Advanced Cancers.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00836927 | Phase 2 | Terminated |
Competing Products
20 competing products in Advanced Cancers